Guidant to pay Cordis $425 million in patent settlement
This article was originally published in Clinica
Guidant is facing a $425m hit in the fourth quarter following the preliminary finding of an arbitration panel in its stent patent dispute with Johnson & Johnson subsidiary Cordis. The company will accrue the amount in the second quarter but hopes that the panel will change its mind; the panel's final finding is expected in August.
You may also be interested in...
Nina Daily, chief marketing officer at the Professional Beauty Association since July 2018, will succeed Steve Sleeper as executive director at the end of June when Sleeper retires. More cosmetics industry appointments.
New round of orders would give the US all the vaccine it needs from the existing mRNA products, taking pressure off AstraZeneca as it experiences manufacturing challenges and the EU considers export restrictions to ensure it gets enough vaccine.
Listerine mouthwash drove J&J’s oral care sales up 11.4% in the fourth quarter. Tylenol for adults was the star of its OTC drug business but weakness of children’s Tylenol products and other OTCs led to flat sales.